For example, denosumab, a new monoclonal antibody targeting RANKL, is an effective treatment of osteoporosis, but its serious side-effects including increased risk of spinal fracture and osteonecrosis, and the rebound effect after stopping denosumab exposure limit its clinical application [40–43]. This evidence concerns the gene TNFSF11 and osteonecrosis.